Mar 10, 20211 min readGeniebiome collaborates with CUHK on clinical trial to study the impact of a microbiome immunity forUpdated: May 4, 2022#InnovationStudy aims to evaluate in elderlies and patients with type 2 diabetes, the impact of G-NiiB Immunity Pro (SIM02) in reduction of vaccine-related adverse reactions and improvement of COVID-19 vaccine efficacy
#InnovationStudy aims to evaluate in elderlies and patients with type 2 diabetes, the impact of G-NiiB Immunity Pro (SIM02) in reduction of vaccine-related adverse reactions and improvement of COVID-19 vaccine efficacy
